Skip to main content
Publications
Ogdie A, Mansfield C , Myers K , Tillett W, Nash P, Leach C, Nowell WB, Gavigan K, Zueger P, McDearmon-Blondell E, Walsh JA. Real-world patient experience and treatment preferences in patients with psoriatic arthritis . Poster presented at the Virtual EULAR 2021 Congress; June 2, 2021. [abstract] Ann Rheum Dis. 2021 Jun; 80(Suppl 1):237. doi: 10.1136/annrheumdis-2021-eular.852
Carrico J , Jia X, Zhao Y, Zhang J, Brodtkorb T , Mendelsohn A, Wu J, Feldman S, Armstrong A. Cost-effectiveness and budget impact of tildrakizumab for the treatment of moderate to severe plaque psoriasis using 2019 drug costs . Poster presented at the 2019 AMCP NEXUS; October 29, 2019. National Harbor, MD. [abstract] J Manag Care Spec Pharm. 2019 Oct; 25(10-a Suppl):S79. doi: 10.18553/jmcp.2019.25.10-a.s1
Gutierrez L , Booth H, Dedman D, Crellin E, Kaye JA, Franzoni C , Arana A , Schmitt-Egenolf M, Sundstrom A, Bystrom C. Case validation of cutaneous lymphoma to minimize protopathic bias . Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):645. doi: 10.1002/pds.4864
Jia X, Zhao Y, Carrico J , Brodtkorb TH , Mendelsohn A, Lowry S, Feldman S, Wu JJ, Armstrong A. Cost-effectiveness analysis of tildrakizumab in patients with moderate to severe plaque psoriasis in the United States . Poster presented at the 2018 AMCP NEXUS; October 24, 2018. Orlando, FL. [abstract] J Manag Care Pharm. 2018 Oct; 24(10-a):S78.
Jia X, Zhao Y, Carrico J , Brodtkorb TH , Mendelsohn A, Lowry S, Feldman S, Armstrong A, Wu JJ. Comparative cost per time in response for tildrakizumab and other targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis in the United States . Poster presented at the 2018 AMCP NEXUS; October 22, 2018. Orlando, FL. [abstract] J Manag Care Pharm. 2018 Oct; 24(10a):S79.
Mease PJ, Gladman DD, Davenport EK , Zhou X , Guerette B, Teng L, Kaura S, Nash P. Improvements in work productivity with up to 104 weeks of apremilast monotherapy: results from a phase 3b, randomized, controlled study in biologic-naive subjects with active psoriatic arthritis . Poster presented at the 5th World Psoriasis & Psoriatic Arthritis Conference 2018; June 27, 2018. Stockholm, Sweden. [abstract] Acta Derm Venereol. 2018 Jun; 98(Suppl 219):14. Previously presented at the 2017 ACR/ARHP Annual Meeting. doi: 10.2340/00015555-2978
Strober B, Blauvelt A, Zhao Y, Milutinovic M, Mollon P, You R, Sherif B , Williams N, Fox T, Augustin M, Lebwohl M. Secukinumab treatment provides more effective relief from patient-reported psoriasis-related pain, itching, and scaling than ustekinumab . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB273. Previously presented at the 24th European Academy of Dermatology and Venereology Congress. doi: 10.1016/j.jaad.2016.02.1054
Korman N, Sofen H, Rich P, Fretzin S, Zhao Y, Herrera V, Mordin M , Williams N, Nyirady J, Tyring S. Secukinumab provides more effective relief from psoriasis impact on personal relationships and influence on clothes worn than etanercept and placebo . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1049
Tyring S, Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, Sherif B , Williams N, Nyirady J, Korman N. Secukinumab provides more effective relief from skin-related quality-of-life impact than etanercept in moderate to severe psoriasis . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1050
Sofen H, Korman N, Rich P, Fretzin S, Zhao Y, Herrera V, Sherif B , McLeod L , Nyirady J, Tyring S. Secukinumab provides more effective relief from skin-related quality-of-life impact than placebo in moderate to severe psoriasis . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1051
Blauvelt A, Korman N, Mollon P, Zhao Y, Milutinovic M, You R, Sherif B , Williams N, Fox T, Augustin M. Secukinumab treatment provides faster and more effective relief from patient-reported quality-of-life impact than ustekinumab in subjects with moderate to severe plaque psoriasis . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5[S1]):AB273. Previously presented at the 24th European Academy of Dermatology and Venereology Congress. doi: 10.1016/j.jaad.2016.02.1053
Strober B, Zhao Y, Tran MH, Gnanasakthy A , Nelson LM , McLeod LD , Mordin M , Gottlieb A, Elewski B, Lebwohl MG. Psychometric evaluation of the Psoriasis Symptom Diary using phase 3 trial data . Poster presented at the 2014 ISPOR 19th Annual International Meeting; May 2014. Montreal, Canada. [abstract] Value Health. 2014 Jun; 17(3):A288. doi: 10.1016/j.jval.2014.03.1676